Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Infectious Disease
•
Transplant Infectious Disease
Do you recommend screening patients in high endemic regions for coccidioidomycosis prior to initiation of anti-TNF inhibitor therapy?
Related Questions
How long do you treat uncomplicated gram-negative rod bacteremia in solid organ transplant recipients?
Do you use letermovir as CMV prophylaxis in solid organ transplant patients?
What is your approach to vaccinations and titers for patients with myeloma, who are immunosuppressed and do not have appropriate antibody responses to vaccines?
What is current best practice with regards to antibacterial prophylaxis in patients with hematologic malignancy and resolved neutropenic fever (>72 hours)?
Have you used oral vancomycin as prophylaxis for C difficile infection in patients admitted for allogeneic hematopoietic cell transplant?
Is there a role for secondary CMV prophylaxis in solid organ transplant patients?
Is there ever a role for the use of CMV immune globulin for treatment of CMV viremia and/or disease?
What is your approach to starting antiretroviral therapy in a patient living with HIV who is diagnosed with cryptococcal meningitis?
What isolation policies are Rheumatology offices employing for both staff and patients diagnosed with COVID-19 given the new CDC guidelines?
For patients on PrEP, is there a role for HIV RNA PCR screening in addition to 4th generation antigen/antibody testing?
